GLP-1 drugs and eating disorder risk examined as Covid impact wanes in 2026
The Morning Rounds newsletter explores the potential link between GLP-1 medications and the development of eating disorders, emphasizing that the risk remains uncertain and warrants further study.
Theresa Gaffney, the lead writer, frames the discussion within a broader health update that also touches on the evolving Covid-19 situation six years after the pandemic's peak, noting that recent flu seasons have affected more people than Covid.
The article also mentions a stylistic shift by the AP Stylebook, which now treats "healthcare" as a single word, reflecting ongoing changes in health-related journalism.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “What’s the true risk for eating disorders with GLP-1s?”
read at STAT ↗
comments(0)
5-min edit window · permanent after that